PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 97627

[Severe anti-D allo-immunization: failure of repeated antenatal plasmapheresis (a case report)].

P Herve·C Coffe·L Lapprand·A Peters·J Selva·J Y Gillet
View original source ↗Export metadata ↓

Abstract

The source did not provide an abstract. Follow the original record for more information.

Explore related subjects

Erythroblastosis, FetalFemaleHumansInfant, NewbornIsoantibodiesPlasmapheresisPregnancyPrenatal CareRh-Hr Blood-Group SystemCase ReportsLetter

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

P Herve, C Coffe, L Lapprand, A Peters, J Selva, J Y Gillet. 1978-06-03. [Severe anti-D allo-immunization: failure of repeated antenatal plasmapheresis (a case report)].. https://pubmed.ncbi.nlm.nih.gov/97627/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed1979

Rh hemolytic disease. Epidemiologic surveillance in the United States, 1968 to 1975.

Nationwide surveillance of Rh hemolytic disease of the newborn showed that associated infant mortality decreased from 941 deaths in 1968 to 269 deaths in 1975, or from 2.7 to 0.9 per 10,000 live births. The incidence of Rh hemolytic disease declined from 45 per 10,000 total births in 1970 to 21 per 10,000 in 1975. In 1970, an estimated 16,000 infants were affected, whereas in 1975, the number was 6,000. Several state-based Rh disease surveillance programs reported declining mortality and incidence and increasing use of Rh immune globulin. Rh immune globulin was administered to an estimated 80% of eligible Rh-negative women in 1974, eighty-one percent in 1975, and 82% in 1976. More concerted efforts are needed to determine the frequency of maternal sensitization and to identify and correct gaps in postpartum and postabortion use of Rh immune globulin.

Erythroblastosis, Fetal↗
PubMed1979

[Anti-D hyperimmunoglobulin, a study of Swiss requirements].

Owing to the introduction of postpartum Rhesus prophylaxis with anti-D hyperimmunoglobulin, a very small number of Rh-negative women become sensitized against the Rhesus factor at birth. Accordingly, the number of naturally immunized women suitable for the collection of anti-D plasma is decreasing. Currently, the demand for anti-D plasma in Switzerland is covered by plasma donations of spontaneously immunized women. The relation between production of and demand for anti-D hyperimmunoglobulin is expected to improve in the coming years due to better registration of anti-D-carrying women. Large areas of Switzerland are poorly exploited with regard to female anti-D donors and represent substantial reserves with regard to anti-D hyperimmunoglobulin production. It is expected that anti-D production from plasma collected from naturally sensitized women will cover demands up to the year 2000 without difficulty. Active immunization of Rh-negative volunteer donors will not be needed before the end of the century.

Erythroblastosis, Fetal↗